(HQH) Tekla Healthcare Investors - Overview
Sector: Financial Services | Industry: Asset Management | Exchange: NYSE (USA) | Market Cap: 968m USD | Total Return: 31% in 12m
Stock
Healthcare, Biotechnology, Pharmaceuticals, Medical Devices
Total Rating 57
Risk 66
Buy Signal 0.28
Market Cap:
968m
Avg Trading Vol: 2.86M USD
Avg Trading Vol: 2.86M USD
ATR:
2.70%
Peers RS (IBD): 83.2
Peers RS (IBD): 83.2
Risk 5d forecast
Volatility27.2%
Rel. Tail Risk2.83%
Reward TTM
Sharpe Ratio0.88
Alpha8.26
Character TTM
Beta0.706
Beta Downside0.600
Drawdowns 3y
Max DD21.14%
CAGR/Max DD0.65
EPS (Earnings per Share)
EPS CAGR: 27.52%
EPS Trend: -11.9%
EPS Trend: -11.9%
Last SUE: 1.67
Qual. Beats: 1
Qual. Beats: 1
Revenue
Rev. CAGR: 15.85%
Rev. Trend: 31.6%
Rev. Trend: 31.6%
Qual. Beats: 0
Description: HQH Tekla Healthcare Investors
Tekla Healthcare Investors (HQH) is a US-based closed-end equity fund managed by abrdn Inc.
The fund invests globally in public healthcare equities, specifically targeting growth-oriented small-cap companies within biotechnology, medical devices, and pharmaceuticals.
Its investment strategy uses fundamental analysis, prioritizing market position, management experience, technological expertise, and financial self-sufficiency or access to capital. The healthcare sector is characterized by high research and development costs and long product development cycles.
HQH benchmarks its performance against the NASDAQ Biotechnology Index, S&P 500 Index, and S&P 1500 Healthcare Index.
To gain further insights into HQHs performance and holdings, consider exploring ValueRays detailed analysis.
- Biotechnology innovation drives portfolio company valuations
- Healthcare regulatory changes impact drug approval timelines
- Small-cap growth stock performance dictates fund returns
- Global healthcare spending trends influence sector outlook
Piotroski VR‑10 (Strict, 0-10)
4.0
| Net Income: 320.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA 0.79 > 1.0 |
| NWC/Revenue: 7.42% < 20% (prev -0.53%; Δ 7.95% < -1%) |
| CFO/TA 0.01 > 3% & CFO 8.72m > Net Income 320.0m |
| Net Debt (-59.0) to EBITDA (99.7m): -0.00 < 3 |
| Current Ratio: 2.15 > 1.5 & < 3 |
| Outstanding Shares: last quarter (55.5m) vs 12m ago 9.65% < -2% |
| Gross Margin: 72.71% > 18% (prev 0.90%; Δ 7.18k% > 0.5%) |
| Asset Turnover: 1.79% > 50% (prev 10.98%; Δ -9.18% > 0%) |
| Interest Coverage Ratio: -0.45 > 6 (EBITDA TTM 99.7m / Interest Expense TTM -220.4m) |
Altman Z''
10.00
| A: 0.00 (Total Current Assets 2.61m - Total Current Liabilities 1.21m) / Total Assets 1.10b |
| B: 0.09 (Retained Earnings 101.6m / Total Assets 1.10b) |
| C: 0.09 (EBIT TTM 99.7m / Avg Total Assets 1.05b) |
| D: 29.63 (Book Value of Equity 101.6m / Total Liabilities 3.43m) |
| Altman-Z'' Score: 32.05 = AAA |
Beneish M
| DSRI: 39.80 (Receivables 2.54m/374k, Revenue 18.9m/110.7m) |
| GMI: 1.24 (GM 72.71% / 90.16%) |
| AQI: none (AQ_t none / AQ_t-1 none) |
| SGI: 0.17 (Revenue 18.9m / 110.7m) |
| TATA: 0.28 (NI 320.0m - CFO 8.72m) / TA 1.10b) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of HQH shares?
As of April 02, 2026, the stock is trading at USD 17.79 with a total of 189,263 shares traded.
Over the past week, the price has changed by -0.22%, over one month by -3.18%, over three months by -0.05% and over the past year by +31.01%.
Over the past week, the price has changed by -0.22%, over one month by -3.18%, over three months by -0.05% and over the past year by +31.01%.
Is HQH a buy, sell or hold?
Tekla Healthcare Investors has no consensus analysts rating.
What are the forecasts/targets for the HQH price?
| ISSUER | TARGET | UP/DOWN |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
HQH Fundamental Data Overview
as of 29 March 2026
P/E Trailing = 10.8261 P/S = 128.4347
P/B = 0.8845
Revenue TTM = 18.9m USD
EBIT TTM = 99.7m USD
EBITDA TTM = 99.7m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = -59.0 USD (from netDebt column, last fiscal year)
Enterprise Value = 967.5m USD (967.5m + (null Debt) - CCE 59.0)
Interest Coverage Ratio = -0.45 (Ebit TTM 99.7m / Interest Expense TTM -220.4m)
EV/FCF = 111.0x (Enterprise Value 967.5m / FCF TTM 8.72m)
FCF Yield = 0.90% (FCF TTM 8.72m / Enterprise Value 967.5m)
FCF Margin = 46.15% (FCF TTM 8.72m / Revenue TTM 18.9m)
Net Margin = 1.69k% (Net Income TTM 320.0m / Revenue TTM 18.9m)
Gross Margin = 72.71% ((Revenue TTM 18.9m - Cost of Revenue TTM 5.15m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 0.88 (Enterprise Value 967.5m / Total Assets 1.10b)
Interest Expense / Debt = unknown (Interest Expense 48.2m / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 78.7m (EBIT 99.7m * (1 - 21.00%))
Current Ratio = 2.15 (Total Current Assets 2.61m / Total Current Liabilities 1.21m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = -0.00 (Net Debt -59.0 / EBITDA 99.7m)
Debt / FCF = -0.00 (Net Debt -59.0 / FCF TTM 8.72m)
Total Stockholder Equity = 1.04b (last 4 quarters mean from totalStockholderEquity)
RoA = 30.39% (Net Income 320.0m / Total Assets 1.10b)
RoE = 30.74% (Net Income TTM 320.0m / Total Stockholder Equity 1.04b)
RoCE = 9.09% (EBIT 99.7m / Capital Employed (Total Assets 1.10b - Current Liab 1.21m))
RoIC = 9.09% (EBIT 99.7m / (Assets 1.10b - Curr.Liab 1.21m - Cash 59.0))
WACC = 8.46% (E(967.5m)/V(967.5m) * Re(8.46%) + (debt-free company))
Discount Rate = 8.46% (= CAPM, Blume Beta Adj.)
[DCF] Terminal Value 68.60% ; FCFF base≈8.72m ; Y1≈5.72m ; Y5≈2.62m
[DCF] Fair Price = 0.86 (EV 48.0m - Net Debt -59.0 = Equity 48.0m / Shares 55.5m; r=8.46% [WACC]; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -11.87 | EPS CAGR: 27.52% | SUE: 1.67 | # QB: 1
Revenue Correlation: 31.65 | Revenue CAGR: 15.85% | SUE: N/A | # QB: 0